ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
Dow Jones
37.903,29
0,23%
Euro vs US Dollar
1,07149
0,46%
Bitcoin
57.932,48
-4,40%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Europa
  5. EU
  6. Inventiva (IVA)

  7. Inventiva (IVA) News

IVA

Inventiva (IVA)

Inventiva
Von:
Sortieren nach:
 Showing the most relevant articles for your search:EU:IVA
DatumZeitQuelleÜberschriftSymbolFirma
03/04/202422h00GlobeNewswire Inc.Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FEU:IVAInventiva
03/04/202422h00GlobeNewswire Inc.Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FEU:IVAInventiva
03/04/202422h00GlobeNewswire Inc.Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)EU:IVAInventiva
28/03/202408h00GlobeNewswire Inc.Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateurEU:IVAInventiva
28/03/202408h00GlobeNewswire Inc.Inventiva announces the nomination of Andre Turenne as DirectorEU:IVAInventiva
28/03/202408h00GlobeNewswire Inc.Inventiva announces the nomination of Andre Turenne as DirectorEU:IVAInventiva
27/03/202421h00GlobeNewswire Inc.Inventiva reports its 2023 full-year resultsEU:IVAInventiva
27/03/202421h00GlobeNewswire Inc.Inventiva publie ses résultats annuels 2023EU:IVAInventiva
27/03/202421h00GlobeNewswire Inc.Inventiva reports its 2023 full-year resultsEU:IVAInventiva
22/03/202421h00GlobeNewswire Inc.Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsEU:IVAInventiva
22/03/202421h00GlobeNewswire Inc.Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsEU:IVAInventiva
22/03/202421h00GlobeNewswire Inc.Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023EU:IVAInventiva
18/03/202421h00GlobeNewswire Inc.Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
18/03/202421h00GlobeNewswire Inc.Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2EU:IVAInventiva
13/03/202421h00GlobeNewswire Inc.Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
13/03/202421h00GlobeNewswire Inc.Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2EU:IVAInventiva
13/03/202421h00GlobeNewswire Inc.Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
07/03/202422h00GlobeNewswire Inc.Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedEU:IVAInventiva
07/03/202422h00GlobeNewswire Inc.Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedEU:IVAInventiva
07/03/202422h00GlobeNewswire Inc.Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH  EU:IVAInventiva
15/02/202422h35GlobeNewswire Inc.Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3EU:IVAInventiva
15/02/202422h35GlobeNewswire Inc.Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3EU:IVAInventiva
15/02/202422h35GlobeNewswire Inc.Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3EU:IVAInventiva
24/01/202422h15GlobeNewswire Inc.Half-Year Review of Inventiva’s Liquidity Contract with Kepler CheuvreuxEU:IVAInventiva
24/01/202422h15GlobeNewswire Inc.Half-Year Review of Inventiva’s Liquidity Contract with Kepler CheuvreuxEU:IVAInventiva
24/01/202422h15GlobeNewswire Inc.Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler CheuvreuxEU:IVAInventiva
10/01/202422h00GlobeNewswire Inc.Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment BankEU:IVAInventiva
10/01/202422h00GlobeNewswire Inc.Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment BankEU:IVAInventiva
10/01/202422h00GlobeNewswire Inc.Inventiva annonce le tirage de la seconde tranche de 25 millions d'euros dans le cadre de son Contrat de Financement avec la Banque Européenne d'InvestissementEU:IVAInventiva
20/12/202322h00GlobeNewswire Inc.Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development programEU:IVAInventiva
 Showing the most relevant articles for your search:EU:IVA

Kürzlich von Ihnen besucht

NYSE
XOM
Exxon Mobil
USOTC
ADDYY
Adidas (QX)
TG
DTE
Deutsche Telekom
TG
RHM
Rheinmetall
TG
BAS
BASF
AMEX
SPY
SPDR S&P 500
AMEX
XLF
Financial Select Sector
DBI
MDAX
MDAX
NYSE
KO
Coca Cola
TG
LHA
Deutsche Lufthansa
CCOM
US100
US Tech 100
TG
MBG
MercedesBenz
NYSE
JPM
JP Morgan Chase
USOTC
DTEGY
Deutsche Telekom (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten